Murine bispecific antibody 1A10 directed to human transferrin receptor and a 42-kDa tumor-associated glycoprotein.
Previously, we observed that bispecific antibodies ("antigen forks") that bound to certain pairs of different tumor surface antigens could inhibit cell growth. The chemically linked heteroconjugate of MAb 454A12 (murine IgG1 recognizing human transferrin receptor) and 317G5 (murine IgG1 recognizing a 42-kDa tumor-associated glycoprotein) was particularly inhibitory toward human colorectal cancer cell lines, and the iron-chelating agent deferoxamine was found to augment inhibition of tumor cell growth by this antigen fork. Further experiments revealed that an antigen fork constructed by linking Fab' fragments instead of whole antibodies retained activity, which led us to construct a fork-secreting hybrid hybridoma. Hybridoma 454A12 was fused with hybridoma 34F2 (murine IgG1 with the same specificity as 317G5). Hybrid hybridomas whose supernatants blocked binding of both 454A12 and 34F2 probes were further tested for the ability to block growth of SW948 human colorectal cancer cells in an MTT growth assay, and were chosen for subcloning. Ascites produced by clone 1A10 was purified by affinity and cation exchange chromatography. Purified 1A10 bispecific antibody showed growth inhibitory activity comparable to that of a chemically linked heteroconjugate of its parental antibodies 34F2 and 454A12. Adding deferoxamine greatly enhanced the inhibitory activity of 1A10 and effectively prevented regrowth of tumor cells in vitro. By heterologously crosslinking two antigens that are coexpressed on many tumor cells, this bispecific antibody is able to inhibit tumor growth with enhanced selectivity.
Shi
T
T
Department of Immunotherapeutics, Chiron Corporation, Emeryville, California 94608, USA.
Hsieh-Ma
S T
ST
Reeder
J
J
Ring
D B
DB
D000818:Animals; D018033:Antibodies, Bispecific / Q000096:biosynthesis / Q000302:isolation & purification; D000918:Antibody Specificity; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000276:immunology*; D001666:Binding Sites, Antibody; D002277:Carcinoma / Q000276:immunology / Q000473:pathology; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D002459:Cell Fusion; D002460:Cell Line; D015179:Colorectal Neoplasms / Q000276:immunology / Q000473:pathology; D003676:Deferoxamine / Q000494:pharmacology; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D006825:Hybridomas; D051379:Mice; D008970:Molecular Weight; D011990:Receptors, Transferrin / Q000276:immunology*; D014407:Tumor Cells, Cultured
D018033:Antibodies, Bispecific; D015295:Antigens, Tumor-Associated, Carbohydrate; D006023:Glycoproteins; D011990:Receptors, Transferrin; D003676:Deferoxamine